CHO Pharma, Inc. (TPEX:6586)
Taiwan
· Delayed Price · Currency is TWD 43.10
-1.40 (-3.15%)
Apr 24, 2025, 1:54 PM CST
CHO Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 3.58 | - | 0.06 | 3.57 | 0.14 | Upgrade
|
| Revenue Growth (YoY) | - | - | -98.32% | 2486.96% | -53.53% | Upgrade
|
| Cost of Revenue | 1.87 | - | 0 | 0.21 | 0.07 | Upgrade
|
| Gross Profit | 1.71 | - | 0.06 | 3.36 | 0.07 | Upgrade
|
| Selling, General & Admin | 31.93 | 29.61 | 24.86 | 20.35 | 21.74 | Upgrade
|
| Research & Development | 219.08 | 239.39 | 326.1 | 193.51 | 287.88 | Upgrade
|
| Operating Expenses | 251 | 269 | 350.96 | 213.85 | 309.62 | Upgrade
|
| Operating Income | -249.29 | -269 | -350.9 | -210.49 | -309.56 | Upgrade
|
| Interest Expense | -0.68 | -0.08 | -0.3 | -0.58 | -0.78 | Upgrade
|
| Interest & Investment Income | 37.68 | 16.24 | 7.05 | 5.46 | 8.11 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.07 | -0.53 | -0.13 | 0.22 | 0.18 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 0.01 | 5.88 | 5.46 | 5.29 | Upgrade
|
| EBT Excluding Unusual Items | -212.23 | -253.36 | -338.39 | -199.93 | -296.75 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.09 | Upgrade
|
| Asset Writedown | - | -52.73 | - | -6 | - | Upgrade
|
| Pretax Income | -212.23 | -306.09 | -338.39 | -205.93 | -296.84 | Upgrade
|
| Net Income | -212.23 | -306.09 | -338.39 | -205.93 | -296.84 | Upgrade
|
| Net Income to Common | -212.23 | -306.09 | -338.39 | -205.93 | -296.84 | Upgrade
|
| Shares Outstanding (Basic) | 214 | 191 | 184 | 184 | 184 | Upgrade
|
| Shares Outstanding (Diluted) | 214 | 191 | 184 | 184 | 184 | Upgrade
|
| Shares Change (YoY) | 11.86% | 4.00% | 0.04% | 0.12% | 0.36% | Upgrade
|
| EPS (Basic) | -0.99 | -1.60 | -1.84 | -1.12 | -1.62 | Upgrade
|
| EPS (Diluted) | -0.99 | -1.60 | -1.84 | -1.12 | -1.62 | Upgrade
|
| Free Cash Flow | -222.87 | -293.13 | -258.9 | -196.11 | -267.89 | Upgrade
|
| Free Cash Flow Per Share | -1.04 | -1.53 | -1.41 | -1.07 | -1.46 | Upgrade
|
| Gross Margin | 47.77% | - | 98.33% | 94.09% | 48.55% | Upgrade
|
| Operating Margin | -6963.49% | - | -584833.33% | -5896.11% | -224315.94% | Upgrade
|
| Profit Margin | -5928.10% | - | -563988.33% | -5768.21% | -215100.73% | Upgrade
|
| Free Cash Flow Margin | -6225.53% | - | -431501.67% | -5493.25% | -194121.74% | Upgrade
|
| EBITDA | -237.71 | -250.3 | -324.67 | -184.88 | -282 | Upgrade
|
| D&A For EBITDA | 11.59 | 18.7 | 26.23 | 25.61 | 27.56 | Upgrade
|
| EBIT | -249.29 | -269 | -350.9 | -210.49 | -309.56 | Upgrade
|
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.